Skip to main content
  • Register
  • Help
  • Contact us
  • Log out of your HL account

Relmada Therapeutics Inc (RLMDD) USD0.001

Sell:$2.63 Buy:$2.63 Change: $0.33 (14.35%)
Market closed |  Prices as at close on 24 May 2019 | Switch to live prices |
Change: $0.33 (14.35%)
Deal now Deal for just £11.95 per trade in a Fund & Share Account
Market closed |  Prices as at close on 24 May 2019 | Switch to live prices |
Change: $0.33 (14.35%)
Market closed |  Prices as at close on 24 May 2019 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Relmada Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing a pipeline of drug candidates to treat chronic pain. Its product candidates include d-Methadone (dextromethadone, REL-1017), LevoCap ER (REL-1015), BuTab (REL-1028) and MepiGel (REL-1021). Its d-Methadone is an N-methyl-D-aspartate (NMDA) receptor antagonist being developed for the treatment of neuropathic pain. Its REL-1015 is an extended release, abuse deterrent formulation of the opioid analgesic levorphanol, which is pharmacologically differentiated from morphine, oxycodone and other opioids for the management of pain severe enough to require daily, around-the-clock and long-term opioid treatment. REL-1028 represents formulations of oral, modified release buprenorphine being developed for both chronic pain and opioid dependence indications. REL-1021 is a topical dosage form of the local anesthetic mepivacaine for the treatment of painful peripheral neuropathies.

Contact details

750 3rd Ave Fl 9
United States
+1 (212) 5479591

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$79.82 million
Shares in issue:
33.26 million
OTC Bulletin Board
United States
US dollar

Key personnel

  • Charles Casamento
    Chairman of the Board
  • Sergio Traversa
    Chief Executive Officer, Interim Chief Financial Officer, Principal Financial and Accounting Officer, Director
  • Ottavio Vitolo
    Senior Vice President, Head of R&D and Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.